Aims: This study aims to evaluate whether intraoperative perineural hyaluronic acid (HA) injection provides additional clinical or electrophysiological benefits beyond standard carpal tunnel release (CTR) in patients with moderate-to-severe carpal tunnel syndrome (CTS).
Methods: In this retrospective cohort study, 130 patients with electrophysiologically confirmed moderate-to-severe CTS underwent either CTR alone (n=66) or CTR with intraoperative perineural HA injection (n=64). HA (Alsegovisc®, 40 mg/2 ml, 1500 kDa) was administered following surgical decompression. Outcomes included pain (Visual Analog Scale, VAS), symptom severity and function (Boston Carpal Tunnel Questionnaire, BCTQ), sensory and motor conduction (SNCV, DML), and achievement of patient-centered benchmarks (minimal clinically important difference, MCID; patient acceptable symptom state, PASS). Evaluations were carried out pre-surgically and at 3- and 6-month intervals following the procedures.
Results: Both groups demonstrated significant improvements in pain (VAS: 7.0 to 2.0), symptom severity (BCTQ-SSS: 45.0 to 18.0), function (BCTQ-FSS: 34.5 to 13.5), and electrophysiological parameters (SNCV: 31.4 to 40.5 m/s; DML: 5.5 to 4.2 ms) over 6 months (all p<0.001). However, The comparison did not yield statistically significant results between groups at any time point (p>0.05), and effect sizes were consistently small (Cohen’s d<0.2). MCID and PASS thresholds were met by >68% of patients in both groups. Subgroup analyses revealed no predictive value for baseline disease severity or thenar atrophy.
Conclusion: Intraoperative perineural HA injection did not confer additional clinical or electrophysiological benefit over CTR alone in moderate-to-severe CTS. Despite compelling preclinical data, HA's efficacy may be attenuated in chronic fibrotic nerve compression due to pharmacokinetic and tissue-level limitations. These findings do not support routine use of intraoperative HA in advanced CTS but highlight the need for future prospective trials targeting earlier-stage disease, sustained-release formulations, or repeated dosing strategies.
Carpal tunnel syndrome hyaluronic acid perineural injection carpal tunnel release moderate to severe neuropathy
This study was approved by the Institutional Ethics Committee of Bursa City Hospital (Approval No: 2025-5/2, Date: 5 March 2025).
Aims: This study aims to evaluate whether intraoperative perineural hyaluronic acid (HA) injection provides additional clinical or electrophysiological benefits beyond standard carpal tunnel release (CTR) in patients with moderate-to-severe carpal tunnel syndrome (CTS).
Methods: In this retrospective cohort study, 130 patients with electrophysiologically confirmed moderate-to-severe CTS underwent either CTR alone (n=66) or CTR with intraoperative perineural HA injection (n=64). HA (Alsegovisc®, 40 mg/2 ml, 1500 kDa) was administered following surgical decompression. Outcomes included pain (Visual Analog Scale, VAS), symptom severity and function (Boston Carpal Tunnel Questionnaire, BCTQ), sensory and motor conduction (SNCV, DML), and achievement of patient-centered benchmarks (minimal clinically important difference, MCID; patient acceptable symptom
state, PASS). Evaluations were carried out pre-surgically and at 3- and 6-month intervals following the procedures.
Results: Both groups demonstrated significant improvements in pain (VAS: 7.0 to 2.0), symptom severity (BCTQ-SSS: 45.0 to 18.0), function (BCTQ-FSS: 34.5 to 13.5), and electrophysiological parameters (SNCV: 31.4 to 40.5 m/s; DML: 5.5 to 4.2 ms) over 6 months (all p<0.001). However, The comparison did not yield statistically significant results between groups at any time point (p>0.05), and effect sizes were consistently small (Cohen’s d<0.2). MCID and PASS thresholds were met by >68% of patients in both groups. Subgroup analyses revealed no predictive value for baseline disease severity or thenar atrophy.
Conclusion: Intraoperative perineural HA injection did not confer additional clinical or electrophysiological benefit over CTR alone in moderate-to-severe CTS. Despite compelling preclinical data, HA's efficacy may be attenuated in chronic fibrotic nerve compression due to pharmacokinetic and tissue-level limitations. These findings do not support routine use of intraoperative HA in advanced CTS but highlight the need for future prospective trials targeting earlier-stage disease, sustained-release formulations, or repeated dosing strategies.
Carpal tunnel syndrome hyaluronic acid perineural injection carpal tunnel release moderate to severe neuropathy
Primary Language | English |
---|---|
Subjects | Orthopaedics |
Journal Section | Research Articles |
Authors | |
Publication Date | July 28, 2025 |
Submission Date | May 27, 2025 |
Acceptance Date | July 7, 2025 |
Published in Issue | Year 2025 Volume: 7 Issue: 4 |
TR DİZİN ULAKBİM and International Indexes (1b)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
Note: Our journal is not WOS indexed and therefore is not classified as Q.
You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser. https://dergipark.org.tr/tr/journal/3449/file/4924/show
Journal Indexes and Platforms:
TR Dizin ULAKBİM, Google Scholar, Crossref, Worldcat (OCLC), DRJI, EuroPub, OpenAIRE, Turkiye Citation Index, Turk Medline, ROAD, ICI World of Journal's, Index Copernicus, ASOS Index, General Impact Factor, Scilit.The indexes of the journal's are;
The platforms of the journal's are;
The indexes/platforms of the journal are;
TR Dizin Ulakbim, Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, ICI World of Journal's, Index Copernicus, Turk Medline, General Impact Factor, Scilit
Journal articles are evaluated as "Double-Blind Peer Review"
All articles published in this journal are licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0)